IVANCA
IntraVenous ANtibiotic Compounding Automation
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0IVANCA project word cloud
Explore the words cloud of the IVANCA project. It provides you a very rough idea of what is the project "IVANCA" about.
Project "IVANCA" data sheet
The following table provides information about the project.
| Coordinator |
NEWICON OY
Organization address contact info |
| Coordinator Country | Finland [FI] |
| Project website | http://www.newicon.fi/ |
| Total cost | 71˙429 € |
| EC max contribution | 50˙000 € (70%) |
| Programme |
1. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument) 2. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies) |
| Code Call | H2020-SMEINST-1-2014 |
| Funding Scheme | SME-1 |
| Starting year | 2015 |
| Duration (year-month-day) | from 2015-03-01 to 2015-08-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | NEWICON OY | FI (KUOPIO) | coordinator | 50˙000.00 |
Map
Project objective
The aging population is driving the demand for health care services to an all-time high. This places pressure to find novel measures of producing health services more efficiently and at a lower cost.
In the sphere of hospital pharmacies, antimicrobials are a leading group of medications. The number of doses administered in EU-based hospitals alone is 330 million. In hospital use antibiotics often need to be administered through intravenous (IV) infusion. The manual compounding of IV antibiotics is very time consuming, especially if conducted in the recommended aseptic conditions. Manual compounding is, however, often conducted in non-aseptic conditions, which exposes the IV medicines to microbial contamination. Contaminated medicines are a serious risk to patients.
Hospitals have already begun to adopt automation in care provision. The currently available compounding robots are not, however, capable of rapidly producing large quantities of IV medicines. The demand levels clearly exceed their capacities.
Newico is a pharmacy and laboratory automation company with a sound client base. With the support of the IVANCA project (IntraVenous ANtibiotic Compounding Automation), the goal of Newico is to commercialize a novel, stand-alone IV antibiotic compounding system. The I.V.ICON boasts a capacity level equivalent to 5,5 ward staff. As the I.V.ICON operates in an aseptic environment the produced IV medicines have a significantly longer shelf life (up to 30 times) and their risk of microbial contamination is in the proximity of zero %. Over ten years of use, the I.V.ICON is expected to bring 2,4 Meur savings to the hospital as compared to manual ward based compounding.
The IVANCA project feasibility study is needed to conduct a more detailed market study, learn from an ongoing hospital pilot, make draft plans on arranging manufacturing, elaborate on user needs, conduct an IPR and regulation study in main target markets and make a more detailed business plan.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IVANCA" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "IVANCA" are provided by the European Opendata Portal: CORDIS opendata.
More projects from the same programme (H2020-EU.2.3.1.;H2020-EU.2.1.2.)
S3D (2015)
Feasibility study to determine the use of ITS technology to replace nuclear density meters in mining, dredging and other areas of hydraulic transport.
Read More